Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cancer Research|April 15, 2000
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemiaM W Deininger, S Vieira, R Mendiola, et al.
Leukemia|August 30, 2002
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myelomaA Krämer, B Schultheis, J Bergmann, et al.
Blood|July 27, 2000
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistanceF X Mahon, M W Deininger, B Schultheis, et al.
British Journal of Cancer|November 15, 2007
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trialT Ernst, K Merx, U Gnad-Vogt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trialH Richly, B Schultheis, I A Adamietz, et al.
British Journal of Cancer|May 10, 2012
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyD Strumberg, M E Scheulen, B Schultheis, et al.
Leukemia|October 31, 2008
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1A Chase, B Schultheis, S Kreil, et al.
British Journal of Cancer|November 13, 2008
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumoursD Strumberg, B Schultheis, I A Adamietz, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyB Schultheis, G Folprecht, J Kuhlmann, et al.
Pageof 3